Anacor Pharmaceuticals, Inc. Announces That It Has Submitted a New Drug Application to the FDA for Tavaborole

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that on July 26, 2013 it submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavaborole, its drug candidate for the topical treatment of onychomycosis. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC